CClinicalTrials.gg
CompletedNCT03307681Updated Sep 30, 2020

Effect of White Potatoes on Glycemic Response, Satiety and Food Intake in Children

An interventional study of White bread and Baked potato with skin in Healthy, sponsored by Toronto Metropolitan University. Completed at 1 site in Canada. Open to participants aged 9 Years to 14 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-09-30.

Sponsored by Toronto Metropolitan University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
9 Years to 14 Years
Sex
All
01

Study summary

The purpose of the present study is to explore the influence of cooking methods on post-prandial glycaemia and its impact on satiety in children.

Read the detailed description

Each of the 5 study sessions will be at least 7 days apart. Either meal skipping, or one of three treatments of white potatoes (a) baked (with skin), (b) mashed, (c) fried French fries, or white bread, prepared on the day of testing, will be served to healthy children (9-14 years). Participants will consume the equivalent to 1 medium sized potato (\~280 kcal) or an equivalent amount of calories from white bread. Glycemic response, insulin, incretin hormones (glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP)), dipeptidyl peptidase 4 (DPP4), and cholecystokinin (CCK) will be measured for 2 h (0, 15, 30, 45, 60, 90 and 120 min) following meal consumption, as well as mood and subjective appetite. An ad libitum test meal will be provided at 120 min to assess food intake suppression.

02

Conditions studied

  • Healthy

Keywords

  • White potatoes
  • Children
  • Satiety
  • Glycaemia
03

Who can participate

Ages eligible
9 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • be between 9 and 14 years of age
  • be healthy, and have been born at term
  • be a native English speaker
  • not be taking any medications
  • not have allergies to potatoes, rice, or beans.
  • normal body weight (between the 5th and 85th BMI percentile for age and gender)

Exclusion criteria

Exclusion Criteria:

  • anyone with food sensitivities or allergies to potatoes or potato-products,
  • smokers
  • diabetic or overweight/obese individuals.
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    White bread

    Matched for energy content and available carbohydrate content of potato treatments

    Other: White bread

  • Experimental
    Baked potato with skin

    Baked russet potato

    Other: Baked potato with skin

  • Experimental
    Mashed potato served hot

    Mashed potatoes prepared from frozen, matched for available carbohydrate content of baked potato

    Other: Mashed potato served hot

  • Experimental
    Fried French fries

    Matched for available carbohydrate content of baked potato

    Other: Fried French fries

  • Experimental
    Meal skipping

    No food given

    Other: Meal skipping

Interventions

  • OtherWhite bread

    Toasted, with canola oil added to match for fat content of French fries (13.9 grams), as well as being matched for energy (280 kilocalories) and available carbohydrate content (33 grams) of potato treatments.

  • OtherBaked potato with skin

    Baked russet potato with canola oil added once baked to match for fat content of French fries, and also matched for the salt content of white bread (280 milligrams).

  • OtherMashed potato served hot

    Mashed potatoes prepared from frozen, with canola oil added to match for fat content of French fries, as well as being matched for energy and available carbohydrate content of the baked potato.

  • OtherFried French fries

    Prepared from frozen, matched for energy and available carbohydrate content of baked potato and salt content of white bread.

  • OtherMeal skipping

    No food given

05

What researchers measure

Primary outcomes

  1. Ad libitum food intake (lunch, at 120 minutes)

    Food intake will be determined by weighing the meal before and after serving. The net weight of the test meal will be converted to calories

    Time frame: at 120 minutes post morning meal consumption

  2. Change from baseline glycemic response

    Blood glucose (mmol/L). Blood glucose will be measured in whole blood using YSI 2300 STAT PLUS (YSI Incorporated, Yellow Springs, OH)

    Time frame: 15, 30, 45, 60, 90, and 120 minutes after meal consumption

  3. Change from baseline insulin

    Blood insulin (pmol/L). Insulin concentration in serum will be determined in duplicate via enzyme-linked immunosorbent assay kits (ELISA; Millipore, Billerica, Massachusetts).

    Time frame: 15, 30, 45, 60, 90, and 120 minutes after meal consumption

Secondary outcomes

  1. Change from baseline subjective appetite

    Measured using visual analogue scale (mm). Each VAS is a 100 mm line where they will place a pencil mark to describe their feelings.

    Time frame: 15, 30, 45, 60, 90, and 120 minutes after meal consumption

  2. Change from baseline mood

    Measured using visual analogue scale (mm). Each VAS is a 100 mm line where they will place a pencil mark to describe their feelings.

    Time frame: 15, 30, 45, 60, 90, and 120 minutes after meal consumption

  3. Change from baseline cholecystokinin (CCK)

    Blood CCK (pmol/L). CCK concentration in serum will be determined in duplicate via enzyme-linked immunosorbent assay kits (ELISA; Millipore, Billerica, Massachusetts).

    Time frame: 15, 30, 45, 60, 90, and 120 minutes after meal consumption

  4. Change from baseline dipeptidyl peptidase 4 (DPP4)

    Blood DPP4 (ng/mL). DPP4 concentration in serum will be determined in duplicate via enzyme-linked immunosorbent assay kits (ELISA; Millipore, Billerica, Massachusetts).

    Time frame: 15, 30, 45, 60, 90, and 120 minutes after meal consumption

  5. Change from baseline glucose-dependent insulinotropic peptide (GIP)

    Blood GIP (pmol/L). GIP concentration in serum will be determined in duplicate via enzyme-linked immunosorbent assay kits (ELISA; Millipore, Billerica, Massachusetts).

    Time frame: 15, 30, 45, 60, 90, and 120 minutes after meal consumption

  6. Change from baseline glucagon-like peptide-1 (GLP-1)

    Blood GLP-1 (pmol/L). GLP-1 concentration in serum will be determined in duplicate via enzyme-linked immunosorbent assay kits (ELISA; Millipore, Billerica, Massachusetts).

    Time frame: 15, 30, 45, 60, 90, and 120 minutes after meal consumption

06

Study locations

1 site
  • School of Nutrition, Ryerson University
    Toronto, Ontario M5B 2K3, Canada
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03307681
Lead sponsor
Toronto Metropolitan University
Responsible party
Nick Bellissimo (Associate Professor, Toronto Metropolitan University) — Principal investigator
First posted
Oct 12, 2017
Start date
Dec 21, 2018
Primary completion
Jun 21, 2020
Completion
Jun 21, 2020
Last update
Sep 30, 2020

Study contacts

Nick Bellissimo, PhD
principal investigator · Toronto Metropolitan University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion